RT Journal Article
SR Electronic
T1 THYROID AUTOIMMUNITY FOLLOWING ALEMTUZUMAB TREATMENT FOR MS
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP e1
OP e1
DO 10.1136/jnnp-2016-315106.163
VO 87
IS 12
A1 Sarah Healy
A1 Taha Nasser
A1 Mark Willis
A1 Ilaria Muller
A1 Katharine Harding
A1 Trevor Pickersgill
A1 Mark Wardle
A1 Colin Dayan
A1 Neil Robertson
YR 2016
UL http://jnnp.bmj.com/content/87/12/e1.72.abstract
AB Introduction Alemtuzumab is effective in active relapsing MS, although autoimmune disease (AID) is a recognised adverse event. We present long-term outcomes of the most common AID (thyroid), in order to inform pre-treatment counselling and subsequent disease management.Methods 87 patients treated with alemtuzumab were followed within an active surveillance program and detailed data collected prospectively. Standard clinical indices, thyroid diagnosis, thyroid function tests, thyroid autoantibodies and treatment were recorded.Results Mean follow-up was 7.4 years. 31 (36%,24F:7M) developed thyroid AID. Mean interval from first treatment was 3.0 years (range 0.8–8.7); peak incidence in years 2–3. 12 (38.7%) patients developed hyperthyroidism, 8 (25.8%) subclinical hyperthyroidism, 8 (25.8%) hypothyroidism and 3 (9.7%) subclinical hypothyroidism. In 23 (74%) patients TPO antibodies were present during the disease course. Of 11 patients with hypothyroidism, 6 (55%) were TRAb positive. All patients received appropriate initial treatment for thyroid dysfunction. Three (9.7%) required propylthiouracil and 5 (16%) radioiodine. Two patients (6%) underwent thyroidectomy. No patients developed thyroid carcinoma.Discussion Thyroid AID following alemtuzumab is a unique model of human autoimmunity and exhibits a variable presentation. When identified early and managed with specialist support it responds to standard treatments. AID can occur outside the recommended 4-year monitoring window and neurologists should remain vigilant for symptoms and have protocols for management.